Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29891666 | 1.00 | SLC15A2 (0.35) | SLC15A2MME | |
| SCHEMBL14604358 | 1.00 | SLC15A2 (0.35) | SLC15A2MME | |
| SCHEMBL30822978 | 1.00 | SLC15A2 (0.35) | SLC15A2MME | |
| SCHEMBL30629016 | 1.00 | SLC15A2 (0.35) | SLC15A2MME | |
| SCHEMBL10856404 | 1.00 | SLC15A2 (0.35) | SLC15A2MME | |
| SCHEMBL29630376 | 1.00 | SLC15A2 (0.35) | SLC15A2MME | |
| SCHEMBL30159237 | 1.00 | SLC15A2 (0.35) | SLC15A2MME | |
| SCHEMBL29519255 | 1.00 | SLC15A2 (0.35) | SLC15A2MME | |
| SCHEMBL30712894 | 1.00 | SLC15A2 (0.35) | SLC15A2MME | |
| SCHEMBL23598223 | 0.97 | MME (0.35) | MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119400538-B | Functional polypeptide modified nano composite magnetic bead, method for detecting beta-secretase by using functional polypeptide modified nano composite magnetic bead and application of functional polypeptide modified nano composite magnetic bead | 甘肃省科学院传感技术研究所 | 2025-04-04 | — | — | CN | claimed |
| CN-119400538-A | Functional polypeptide modified nano composite magnetic bead, method for detecting beta-secretase by using functional polypeptide modified nano composite magnetic bead and application of functional polypeptide modified nano composite magnetic bead | 甘肃省科学院传感技术研究所 | 2025-02-07 | — | — | CN | claimed |
| US-20240298636-A1 | ANTIMICROBIAL AGENTS AND FILMS MADE THEREFROM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2024-09-12 | — | — | US | claimed |
| US-20240190994-A1 | FUSION PROTEIN BETWEEN ANTIGEN-BINDING MOLECULE AND STREPTAVIDIN VARIANT | THE UNIVERSITY OF TOKYO (JP) | 2024-06-13 | — | — | US | claimed |
| CN-117756893-A | EGFR (epidermal growth factor receptor) inhibition polypeptide compound and preparation method and application thereof | 无锡市人民医院 | 2024-03-26 | — | — | CN | claimed |
| EP-4329492-A1 | ANTIMICROBIAL AGENTS AND FILMS MADE THEREFROM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2024-03-06 | — | — | EP | claimed |
| EP-4321538-A1 | FUSION PROTEIN BETWEEN ANTIGEN-BINDING MOLECULE AND STREPTAVIDIN VARIANT | The University of Tokyo (JP) | 2024-02-14 | — | — | EP | claimed |
| CN-111944061-B | Glucagon-like peptide-1 analogue monomer, dimer and application thereof | 广东药科大学 | 2023-03-10 | — | — | CN | claimed |
| WO-2022229951-A1 | ANTIMICROBIAL AGENTS AND FILMS MADE THEREFROM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2022-11-03 | — | — | WO | claimed |
| WO-2022203000-A1 | FUSION PROTEIN BETWEEN ANTIGEN-BINDING MOLECULE AND STREPTAVIDIN VARIANT | 国立大学法人 東京大学 | 2022-09-29 | — | — | WO | claimed |
| CN-114456276-A | Preparation method and application of long-acting exenatide | 中国科学院大学宁波华美医院 | 2022-05-10 | — | — | CN | claimed |
| EP-4748447-A2 | INFLUENZA VIRUS VACCINES AND USES THEREOF | Icahn School of Medicine at Mount Sinai (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-122070294-A | Stable vitreous material based on histidine, arginine and glutamic acid amino acids | 阵序补丁有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20260108614-A1 | IMMOBILIZED ENDOGLYCOSIDASE FUSION PROTEIN AND USE THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2026-04-23 | — | — | US | disclosed |
| US-20140141468-A1 | BACTERIAL HOST STRAIN EXPRESSING RECOMBINANT DSBC | UCB PHARMA, S.A. (BE) | 2014-05-22 | — | — | US | disclosed |
| EP-2731973-A1 | BACTERIAL HOST STRAIN EXPRESSING RECOMBINANT DSBC | UCB Pharma, S.A. (BE) | 2014-05-21 | — | — | EP | disclosed |
| WO-2013135894-A1 | VERSATILE FUNCTIONALIZATION OF CARBON NANOSTRUCTURES | UNIVERSITE DE STRASBOURG (FR) | 2013-09-19 | — | — | WO | disclosed |
| WO-2013122617-A1 | FACTOR VIII COMPOSITIONS AND METHODS OF MAKING AND USING SAME | AMUNIX OPERATING INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| WO-2013007388-A1 | BACTERIAL HOST STRAIN EXPRESSING RECOMBINANT DSBC | UCB PHARMA, S.A. (BE) | 2013-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190994-A1 | FUSION PROTEIN BETWEEN ANTIGEN-BINDING MOLECULE AND STREPTAVIDIN VARIANT | IGSF11, SPEN, SET | SLC15A2 2355/4885MME 1423/4885 |
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | SLC15A2 4343/4885MME 1936/4885 |
| US-20260108614-A1 | IMMOBILIZED ENDOGLYCOSIDASE FUSION PROTEIN AND USE THEREOF | ENGASE, MGAT3, OGA | SLC15A2 2081/4885MME 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.